| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SGLT4 |
| Entrez GeneID | 200010; |
| WB Predicted band size | 74kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to residues near the C terminal of human solute carrier family 5 (sodium/sugar cotransporter), member 9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SLC5A9抗体的参考文献示例(注：以下为虚构示例，仅作格式参考)：
1. **文献名称**: "Characterization of SLC5A9/SGLT4 antibody specificity in human intestinal epithelia"
**作者**: Smith A, et al.
**摘要**: 本研究验证了一种兔源多克隆SLC5A9抗体的特异性，通过Western blot和免疫组化证实其在人肠道上皮细胞中的表达定位，揭示了SLC5A9在果糖吸收中的潜在作用。
2. **文献名称**: "SLC5A9 expression profiling in renal proximal tubules using a novel monoclonal antibody"
**作者**: Tanaka K, et al.
**摘要**: 开发并验证了一种小鼠单克隆SLC5A9抗体，用于免疫荧光定位肾脏近端小管中的蛋白表达，发现其与钠依赖性葡萄糖转运功能相关。
3. **文献名称**: "SLC5A9 as a biomarker in colorectal cancer: Validation of an antibody-based detection assay"
**作者**: Lee H, et al.
**摘要**: 通过免疫组化验证商业化SLC5A9抗体的可靠性，发现其在结直肠癌组织中高表达，且与患者生存率显著相关。
4. **文献名称**: "Comparative analysis of SLC5A9 antibody performance across species"
**作者**: Müller R, et al.
**摘要**: 评估了多种SLC5A9抗体在小鼠、大鼠及人类组织中的交叉反应性，确定了适用于跨物种研究的抗体克隆及最佳实验条件。
(注：实际文献需通过学术数据库检索确认。)
SLC5A9. also known as sodium/glucose cotransporter 4 (SGLT4), is a member of the solute carrier family 5 (SLC5) that facilitates sodium-dependent transport of glucose, mannose, and water-soluble vitamins across cell membranes. Primarily expressed in the kidney, intestine, and liver, SLC5A9 plays a role in glucose homeostasis and nutrient absorption. Its function is distinct from other SGLT isoforms, such as SGLT1 (SLC5A1) and SGLT2 (SLC5A2), due to its broader substrate specificity and tissue distribution.
Antibodies targeting SLC5A9 are essential tools for studying its expression, localization, and physiological roles. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate SLC5A9's involvement in metabolic disorders, including diabetes and renal dysfunction. Research has also explored its potential role in cancer, where altered SLC5A9 expression may influence tumor cell metabolism.
Commercial SLC5A9 antibodies are typically raised against specific epitopes, such as cytoplasmic or extracellular domains, and validated for species cross-reactivity (e.g., human, mouse, rat). Validation methods often include knockout cell lines or tissues to confirm specificity. Despite its emerging significance, SLC5A9's regulatory mechanisms and pathophysiological contributions remain understudied, necessitating reliable antibodies for ongoing research into its therapeutic potential and biomarker applications.
×
